Revelation Biosciences, Inc. REVB
3.88 USD +0.06 (+1.57%)
Regular-session close
3.90 +0.02 +0.52%
After hours · Nov 17, 4:00 PM ET
3.75 Day range 3.98
3.08 52-week range 40.60
- YTD
- +21.25%
- 1 year
- +9.92%
News
benzinga.com Revelation Biosciences Plans Accelerate Development Of Its Therapeutic Candidate Gemini; New Streamlined Phase 2a Study In Acute Kidney Injury To Deliver Topline Data In 2027 At Nearly 90% Lower Costs The strategy includes advancing a streamlined Phase 2a clinical study in patients with stage 2 or 3 acute kidney injury (AKI) to generate safety and efficacy data more rapidly and at substantially…
businesswire.com Revelation Biosciences Announces Accelerated Gemini Development Plan and Strategic Partnership Initiatives SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developing innovative therapies designed…benzinga.com Revelation Biosciences Q3 EPS $(5.92) Beats $(6.16) Estimate Revelation Biosciences (NASDAQ:REVB) reported quarterly losses of $(5.92) per share which beat the analyst consensus estimate of $(6.16) by 3.9 percent. This is a 88.04 percent increase over losses…
businesswire.com Revelation Biosciences, Inc. Announces Financial Results For the Three and Nine Months Ended September 30, 2026 SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developing innovative solutions to treat…
gurufocus.com Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026 [url="]Revelation Biosciences, Inc.[/url] (NASDAQ: REVB) (the âCompanyâ or âRevelationâ), a clinical-stage life sciences company developing innovative s
businesswire.com Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026 SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developing innovative solutions to treat…
businesswire.com Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developing innovative solutions to treat…
accessnewswire.com Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026 SAN DIEGO, CA / ACCESS Newswire / August 6, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions…
accessnewswire.com Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury SAN DIEGO, CA / ACCESS Newswire / August 3, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions…
accessnewswire.com Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, CA / ACCESS Newswire / July 21, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to…
accessnewswire.com Revelation Biosciences Announces Adoption of Stockholder Rights Plan SAN DIEGO, CA / ACCESS Newswire / July 10, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to…
accessnewswire.com Revelation Biosciences Expands Acute Kidney Injury Advisory Board SAN DIEGO, CA / ACCESS Newswire / June 1, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to…
accessnewswire.com Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders SAN DIEGO, CA / ACCESS Newswire / May 11, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to…
accessnewswire.com Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026 SAN DIEGO, CA / ACCESS Newswire / May 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to…
accessnewswire.com Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board SAN DIEGO, CA / ACCESS Newswire / April 6, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to…
accessnewswire.com Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study - A majority of CKD patients present with cellular inflammation and immunoparalysis predose - -Gemini durably normalizes cellular inflammation and restores immunocompetence - SAN DIEGO, CA / ACCESS…
accessnewswire.com REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference SAN DIEGO, CA / ACCESS Newswire / March 24, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing…
accessnewswire.com Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference SAN DIEGO, CA / ACCESS Newswire / March 19, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing…
defenseworld.net Revelation Biosciences, Inc. (NASDAQ:REVB) Short Interest Update Revelation Biosciences, Inc. (NASDAQ: REVB - Get Free Report) was the target of a large drop in short interest during the month of February. As of February 13th, there was short interest totaling…
accessnewswire.com Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025 SAN DIEGO, CA / ACCESS Newswire / February 26, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing…
accessnewswire.com Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026 SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 26, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), announced today that, on January 28, 2026, the Company will…
accessnewswire.com Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds SAN DIEGO, CA / ACCESS Newswire / January 23, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing…
